Randomized controlled trials (RCTs) are the gold standard for regulatory approval. However, cancer trial participants are often not representative of real-world patient populations. As a result, patient outcomes may not mirror those found in trials. In a new article published on OncLive, Maurie […]
Improving Access to Cancer Therapeutics Through Value-based Care
Qatar provides free cancer care, greatly improving health outcomes at a substantial cost. A newly published pre-print paper in BMC Health Sciences Research examines and puts forward value-based care strategies for cancer care and value-assessment models to help reduce the financial burden of […]
Pfizer is a Fan of FDA’s Real-Time Oncology Application Review Process
Pfizer has expressed positivity towards the US Food and Drug Administration’s (FDA’s) Real-Time Oncology Review (RTOR) program. The RTOR will allow data submissions earlier in the review process in order to accelerate future decision-making and market access. Although the Alliance for Regenerative […]
US Drug Pricing Reform May Help Medicare Part D Beneficiaries with High Cancer Costs
Many US cancer patients enrolled in Medicare Part D programs forgo life-saving cancer care due to exorbitant treatment costs, which average out to $3,000 out-of-pocket for the first month’s prescription. According to a White House blog posted last Friday, April 23rd, new provisions in the Inflation […]
Cancer Treatments in Limbo Due to Abortion Bans
The cancer care for many US patients is in peril due to the legal consequences of the wave of abortion bans following the repeal of Roe v. Wade. States like Georgia have adopted laws that have legal ambiguity in definitions of medically-necessary abortion. As a result some patients will likely be […]
BioGene Scores NICE Approval for Rare Lymphoma Drug Brukinsa
The UK’s National Institute for Health and Care Excellence (NICE) has approved BioGene’s drug Brukinsa for patients with Waldenstrom macroglobulinemia (WM), a rare form of B-cell lymphoma. The drug, approved for the same purpose last year in the US, will meet a previously unmet need due to issues […]
Webinar – A Journey without a Map: Building an Oncology Powerhouse Where Innovation Thrives – Sept. 21
The landscape of next-generation cancer treatment development is rapidly changing. Achieving success in advanced requires careful consideration of the shifting tides of the industry and quick adoption of new concepts and technologies. In an upcoming Endpoints webinar on September 21st, leaders from […]
Pfizer’s Oncology Chief Schmeltz Moves to Rare Disease Role
Pfizer is having another executive shakeup. Andy Schmeltz will leave his role as global president of oncology at Pfizer to take on a new role of managing the pharma juggernaut’s investment strategies. Suneet Varma will leave his position as the head of Pfizer’s rare disease division to fill in […]
Whitepaper: Making APAC the Oncology Clinical Trial Destination
A new whitepaper from Premier Research makes the case that the Asia-Pacific (APAC) Region is the hot spot for oncology clinical trials. Currently, APAC stands as the region with the most ongoing oncology trials worldwide, with the number of active trials growing 138% over the last 10 years. In the […]
Value in Health: Defining a Core Data Set for the Economic Evaluation of Precision Oncology
Despite the growing abundance of multiomic data in precision oncology, the lack of standardization and interoperability impedes economic evaluation. In the latest issue of Value in Health, Samantha Pollard, PhD et al. found significant variability in published data resources. Through their work, […]
